Study of LY4006896 for Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests an investigational drug called LY4006896 in healthy people and in people with Parkinson's disease. It aims to see if the drug is safe and how it affects the body, which may help in developing a new treatment for Parkinson's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For the first part (healthy volunteers): You must be between 30 and 85 years old and generally healthy.
- For the second part (Parkinson's patients): You must be between 40 and 85 years old and have a diagnosis of Parkinson's disease.
- If you are taking Parkinson's medication, your dose must have been stable for at least 90 days and not expected to change for a year.
- You must have a body mass index (BMI) between 18 and 34.
- You must not have significant heart, blood pressure, or other unstable medical conditions.
- You must not have severe allergies or a history of allergic reactions to certain antibodies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This study tests a new drug called HL-400 for the first time in people. It checks how safe the drug is and how the body handles it, to see if it could be developed for future patients.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.